Corpus callosum in neurodegenerative diseases

Findings in Parkinson's disease

Katie Wiltshire, Sheri Foster, Jeffrey Kaye, Brent J. Small, Richard Camicioli

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T1-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% CI, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p <0.01) but not in PDD patients (R = 0.18, p > 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to - 0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.

Original languageEnglish (US)
Pages (from-to)345-351
Number of pages7
JournalDementia and Geriatric Cognitive Disorders
Volume20
Issue number6
DOIs
StatePublished - Nov 2005

Fingerprint

Corpus Callosum
Neurodegenerative Diseases
Parkinson Disease
Alzheimer Disease
Dementia
Atrophy
Progressive Supranuclear Palsy
Frontotemporal Dementia
Meta-Analysis
PubMed
Publications
Differential Diagnosis
Pathology

Keywords

  • Corpus callosum
  • Dementia
  • Magnetic resonance imaging
  • Meta-analysis
  • Neurodegenerative disease
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Geriatrics and Gerontology

Cite this

Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease. / Wiltshire, Katie; Foster, Sheri; Kaye, Jeffrey; Small, Brent J.; Camicioli, Richard.

In: Dementia and Geriatric Cognitive Disorders, Vol. 20, No. 6, 11.2005, p. 345-351.

Research output: Contribution to journalArticle

Wiltshire, Katie ; Foster, Sheri ; Kaye, Jeffrey ; Small, Brent J. ; Camicioli, Richard. / Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease. In: Dementia and Geriatric Cognitive Disorders. 2005 ; Vol. 20, No. 6. pp. 345-351.
@article{f29ac09baee943a4be5df4fd21c884e4,
title = "Corpus callosum in neurodegenerative diseases: Findings in Parkinson's disease",
abstract = "Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T1-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95{\%} CI, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p <0.01) but not in PDD patients (R = 0.18, p > 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to - 0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.",
keywords = "Corpus callosum, Dementia, Magnetic resonance imaging, Meta-analysis, Neurodegenerative disease, Parkinson's disease",
author = "Katie Wiltshire and Sheri Foster and Jeffrey Kaye and Small, {Brent J.} and Richard Camicioli",
year = "2005",
month = "11",
doi = "10.1159/000088526",
language = "English (US)",
volume = "20",
pages = "345--351",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Corpus callosum in neurodegenerative diseases

T2 - Findings in Parkinson's disease

AU - Wiltshire, Katie

AU - Foster, Sheri

AU - Kaye, Jeffrey

AU - Small, Brent J.

AU - Camicioli, Richard

PY - 2005/11

Y1 - 2005/11

N2 - Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T1-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% CI, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p <0.01) but not in PDD patients (R = 0.18, p > 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to - 0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.

AB - Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T1-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% CI, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p <0.01) but not in PDD patients (R = 0.18, p > 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to - 0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.

KW - Corpus callosum

KW - Dementia

KW - Magnetic resonance imaging

KW - Meta-analysis

KW - Neurodegenerative disease

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=27844533593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844533593&partnerID=8YFLogxK

U2 - 10.1159/000088526

DO - 10.1159/000088526

M3 - Article

VL - 20

SP - 345

EP - 351

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 6

ER -